CD4 News and Research

RSS

New guidelines outline key new actions to improve delivery of HIV testing, treatment and care

These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living with HIV who are being treated for tuberculosis.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

New approach to cancer immunotherapy may prevent autoimmunity

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments.

19 Mar 2021

Antidiabetic drug could help reduce chronic inflammation in people living with HIV

Metformin, a drug used to treat type-2 diabetes, could help reduce chronic inflammation in people living with HIV (PLWH) who are being treated with antiretroviral therapy (ART), according to researchers at the University of Montreal Hospital Research Centre.

18 Mar 2021

Researchers explore difference in reactions to SARS-CoV-2 infection between children and adults

The COVID-19 pandemic has claimed over 2.67 million lives in less than a year and a half. However, it is uncommon in children, with less than 2% of the cases being in individuals below the age of 19. Most of these are of mild severity, with the clinical features of severe COVID-19 being rare in this age group.

17 Mar 2021

COVID-19 is more difficult to diagnose in children and adolescents, finds study

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.

17 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Inflammation linked to intensity of tobacco smoking among HIV-positive people

Inflammation in the body has been linked to the intensity of tobacco smoking among people with HIV, according to a team of University of Massachusetts Amherst researchers.

8 Mar 2021

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

A recent study reports the safety and high efficacy of an adjuvanted vaccine candidate against SARS-CoV-2 and the complications of COVID-19.

5 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Researchers from California in the United States have conducted a study showing that important adaptive immune responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not affected by four recently emerged variants of the virus.

3 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021

Researchers examine long-term immune responses following COVID-19 across clinically diverse cohort

A new study by researchers at the University of California, San Francisco, discusses the different aspects of long-term immune responses in a wide sample of patients, as well as how they vary in clinical severity and sequelae.

3 Mar 2021

Protein kinase inhibitors could help treat immunodeficiency in HIV patients

HIV infections are treated with antiviral drugs which effectively prevent the disease from developing. While pharmacological HIV therapy has advanced considerably, the virus cannot be entirely eliminated from the body with currently available drugs.

1 Mar 2021

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Researchers investigated the significance of a transmembrane glycoprotein basigin, or CD147, as a host cell co-receptor required for the entry of SARS-CoV-2. The findings reveal that recombinant human basigin does not interact with full-length spike protein or spike RBD of SARS-CoV-2.

24 Feb 2021

Hyperactive immune system contributes to COVID-19 severity, lung damage

Researchers have pinpointed a helper T cell population in the lungs of patients with severe COVID-19 that may be central to the development of hyperinflammation, lung injury, and subsequent acute respiratory distress syndrome (ARDS) during disease.

24 Feb 2021

CD4 News and Research

New guidelines outline key new actions to improve delivery of HIV testing, treatment and care

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New approach to cancer immunotherapy may prevent autoimmunity

Antidiabetic drug could help reduce chronic inflammation in people living with HIV

Researchers explore difference in reactions to SARS-CoV-2 infection between children and adults

COVID-19 is more difficult to diagnose in children and adolescents, finds study

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Inflammation linked to intensity of tobacco smoking among HIV-positive people

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Researchers examine long-term immune responses following COVID-19 across clinically diverse cohort

Protein kinase inhibitors could help treat immunodeficiency in HIV patients

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Hyperactive immune system contributes to COVID-19 severity, lung damage

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News